Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Zoe Brown ¹, Robert Metcalf ², Jana Bednarz ³, Christiana Stavrou ⁴, Llewellyn Spargo ², Michael James ² and Susanna Proudman⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Rheumatology Unit, The Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³Adelaide Health Technology Assessment, The University of Adelaide, Adelaide, South Australia, Australia, ⁴University College London Hospital, London, United Kingdom, ⁵University of Adelaide, Adelaide, Australia
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…
Abstract Number: 107 • 2019 ACR/ARP Annual Meeting
Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium
William Murray-Brown¹, Yanxia Guo ², Mihir Wechalekar ¹, Helen Weedon ¹, Malcolm Smith ¹, Susanna Proudman ³, Navin Rao ⁴, Sunil Nagpal ⁴ and Mihir Wechalekar ¹, ¹Flinders University, Adelaide, Australia, ²Janssen Research, Spring House, ³Adelaide University, Adelaide, Australia, ⁴Janssen R&D, Spring House, PA
Background/Purpose: Programmed cell death protein 1 (PD-1) expressing T-cells are implicated in the pathogenesis of autoimmune inflammatory diseases such as rheumatoid arthritis (RA). In secondary…
Abstract Number: 1182 • 2019 ACR/ARP Annual Meeting
Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach
Yogan Kisten¹, Adrian Levitsky ¹, Hamed Rezaei ¹, Aase Hensvold ², Per Larsson ³, Erik af Klint ¹, Ronald van Vollenhoven ⁴ and Anca Catrina ⁵, ¹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ³Center for Rheumatology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁴Amsterdam Rheumatology and immunology Center, Netherlands., Amsterdam, Netherlands, ⁵Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Among the arsenal of available techniques for arthritis prediction and diagnosis, fluorescence optical imaging (FOI) has shown to be useful in detecting clinically manifest…
Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
isabel Hernandez Rodriguez¹, Zulema Rosales Rosado ¹, pia Lois ¹, Cristina Lajas ¹, Judit Font Urgelles ², Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…
Abstract Number: 179 • 2019 ACR/ARP Annual Meeting
The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Sofia Pazmino ¹, Veerle Stouten ¹, Patrick Verschueren ², Pavlos Mamouris ¹, Rene Westhovens ³, Kurt De Vlam ², Delphine Bertrand ¹, Kristien Van der Elst ², Bert Vaes ¹ and Diederik De Cock¹, ¹KU Leuven, Leuven, Belgium, ²University Hospital Leuven, Leuven, Belgium, ³University Hospitals, Leuven, Belgium
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…
Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting
Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan J. Bartlett ², Marie-France Valois ³, Louis Bessette ⁴, Gilles Boire ⁵, Glen Hazlewood ⁶, Carol Hitchon ⁷, Edward Keystone ⁸, Janet Pope ⁹, Carter Thorne ¹⁰, Diane Tin ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹University of Toronto, Montreal, Canada, ²McGill University, Montreal, QC, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec City, QC, Canada, ⁵Sherbrooke University, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁹Western University, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…
Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Theodore Pincus¹, jaquelin Chua ², Joel Block ² and Isabel Castrejon ², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, chicago, IL
Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…
Abstract Number: 198 • 2019 ACR/ARP Annual Meeting
Assessing Care Quality in Rheumatology Services
Mark Yates¹, Sam Norton ¹, Alexander MacGregor ², Katie Bechman ³, Sanketh Rampes ³ and James Galloway ⁴, ¹Kings College London, London, ²University of East Anglia, Norwich, United Kingdom, ³King's College London, London, United Kingdom, ⁴Kings College London, London, United Kingdom
Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting
Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
Virginia Muir ¹, Cliff Rims ¹, Kevin Deane ², Jeffrey Carlin ³, Sylvia Posso ¹, Sunil Nagpal ⁴, Navin Rao ⁴, Frédéric Baribaud ⁵, George Vratsanos ⁶, William Robinson ⁷, Gary Firestein ⁸, V. Michael Holers ⁹, Peter Linsley ¹, Eddie James¹ and Jane Buckner ¹, ¹Benaroya Research Institute, Seattle, WA, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³Virginia Mason Medical Center, Seattle, WA, ⁴Janssen R&D, Spring House, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶JNJ, Raritan, NJ, ⁷Stanford University, Palo Alto, CA, ⁸University of California, San Diego, San Diego, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Malin C Erlandsson^1,2, Minna Turkkila³, Rille Pullerits^2,3,4 and Maria I Bokarewa^2,3, ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
Abstract Number: 1486 • 2018 ACR/ARHP Annual Meeting
Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
Michaela Koehm^1,2, Ulf Henkemeier^2,3, Tanja Rossmanith², Stephanie Dauth², Timm Oberwahrenbrock², Ann Christina Foldenauer², Karola Mergenthal⁴, Harald Burkhardt^2,3,5 and Frank Behrens^2,3,5, ¹Division of Rheumatology Goethe-University Frankfurt, Frankfurt/Main, Germany, ²Fraunhofer IME Branch for Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ³Centre of Innovative Diagnostics and Therapeutics Rheumatology / Immunology at University Hospital Goethe-University Frankfurt, Frankfurt, Germany, ⁴Institute for General Practice Goethe-University, Frankfurt, Germany, ⁵Division of Rheumatology Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting approx. 1% of the adult population of Northern Europe and North America. Strategies for…
Abstract Number: 1488 • 2018 ACR/ARHP Annual Meeting
Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
Patrick Durez¹, Sofie Robert², Alexandra Thiry³ and Harris A Ahmad³, ¹Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Bristol-Myers Squibb, Braine L’Alleud, Belgium, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patients (pts) with early RA often present with multiple and different areas of joint involvement. While the ACR and EULAR guidelines specify high disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].